← TrialMatch
HomeTrials

Probiotics on Sperm Quality in Male Infertility Patients

This randomized, placebo-controlled pilot study aims to evaluate the effects of probiotic supplementation on sperm quality in male patients diagnosed with infertility. Male infertility accounts for approximately 40% of all infertility cases and is closely related to abnormalities in sperm count, motility, and morpholog

Condition(s)Male Infertility, Oligozoospermia, Asthenozoospermia, Teratozoospermia, Oligoasthenoteratozoospermia
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryThis randomized, placebo-controlled pilot study aims to evaluate the effects of probiotic supplementation on sperm quality in male patients diagnosed with infertility. Male infertility accounts for approximately 40% of all infertility cases and is closely related to abnormalities in sperm count, motility, and morphology. Factors such as oxidative stress, inflammation, and DNA fragmentation are known to impact sperm function and subsequent fertilization potential negatively. Probiotics are microorganisms that confer health benefits by improving the intestinal microenvironment and regulating immunity. Emerging research suggests that probiotics may reduce oxidative stress and DNA fragmentation in men with asthenozoospermia; however, clinical data on human sperm remains limited. This study see
Who can participateInclusion Criteria: * Males aged 20 to 45 years * Diagnosis of unexplained oligozoospermia, asthenozoospermia, or oligoasthenoteratozoospermia * Sperm concentration \< 5 x 10\^6/mL * Sperm total motility \< 40% * Sperm morphology (Kruger strict criteria) \< 4% Exclusion Criteria: * History of hormonal disorders or epididymo-orchitis * Substance abuse, including drugs or excessive alcohol consumption * Diabetes mellitus * Kidney disease (defined as a doubling of creatinine levels or more) * Chronic liver disease * Varicocele * Current use of medications that interfere with hormones * Occupational or environmental exposure to pesticides, heavy metals, or solvents * Intake of antioxidant supplements within the past three months * Body Mass Index (BMI) of 30 kg/m\^2 or higher
Ages20 Years to 45 Years
SexMale
Lead sponsorMackay Memorial Hospital
LocationsNew Taipei City, Taiwan
Start date2023-09-16
NCT IDNCT07345455
Official listinghttps://clinicaltrials.gov/study/NCT07345455

🔍 Search all trials →